The Beijing Biotechnology Institute and the company Cansino Biologics, working together to develop a COVID-19 vaccine, announced the results of the first phase I vaccine to be introduced in the world. The 108 volunteers who participated in the experiment tolerated the vaccine, making it safe, according to an article published in the respected medical journal The Lancet. It also allowed patients to build anticorps of the type T.
The adverse symptoms presented by the participants were injection site pain, nausea, tiredness, headache and muscle pain. Yet, in all cases, the severity was mild or moderate. Different types of antibodies increased dramatically in accordance with the T cell ‘s unique response, suggesting that defensive mechanisms were produced against the virus. The antibodies “significantly increased on day 14 and peaked 28 days after vaccination,” according to the report, so the results warrant further investigation.
It should be remembered that these results do not mean the vaccine is safe. While trials with 500 patients have been included since the beginning of Phase II in April to further determine the dose which is adequate to protect against SARS-CoV-2 infection, the virus that causes COVID-19. Over 100 programs worldwide are being supported to develop a SARS-CoV-2 vaccine and its medical implications. Another group, which belongs to the United States, is preparing to begin phase III of a vaccine early, which will be available in the fall if it succeeds. You may be interested: The EU sets aside 300 million doses of experimental COVID-19 vaccine